15 percent. That's the rough mean body weight reduction the top dose tier (2.4 mg weekly) hit at 68 weeks in the published Phase 3 weight-management trial. Not the biggest number in the incretin class. But the longest track record by a wide margin.
Semaglutide is the foundational GLP-1 research compound. Over a decade of Phase 3 data across type 2 diabetes and weight-management populations. Consistent outcomes on body weight, HbA1c, and cardiovascular markers. This piece walks through the trial numbers, the four GLP-1 effects, the standard 40 to 52 week research cycle, and where semaglutide sits versus the newer compounds.
What does the Semaglutide Phase 3 trial show in detail?
Semaglutide has been studied across the broadest population base of any GLP-1 compound. The key reported outcomes:
- Mean body weight reduction at the top weight-management dose (2.4 mg weekly) of roughly 14 to 17 percent over 68 weeks in the published Phase 3 weight-management program.
- HbA1c reductions of 1.5 to 1.8 percentage points in type 2 diabetes populations at 1.0 mg weekly.
- Cardiovascular outcomes data showing reduction in major adverse cardiovascular events in the Phase 3 cardiovascular outcomes trial program.
- GI side effect profile consistent with the GLP-1 class. Nausea most common. Lower appetite by design.
- Mean heart rate rise of 1 to 4 BPM over baseline.
Mechanism: the four GLP-1 effects
Semaglutide is a synthetic peptide copy of the human GLP-1 hormone, with a fatty acid side chain that binds plasma albumin. That side chain gives it the long (about 7-day) plasma half-life that supports once-weekly subcutaneous dosing.
GLP-1 receptor activation produces four research-relevant effects:
- Slower gastric emptying. Food stays in the stomach longer, which extends satiety from each meal.
- Stronger glucose-dependent insulin release. The "glucose-dependent" part matters: insulin release ramps up when blood glucose is high, and stays flat when glucose is normal. That's why hypoglycemia risk is low in non-diabetic researchers.
- Lower after-meal glucagon. Less liver glucose output after eating.
- Central appetite suppression. Action on appetite-regulating brain regions, lowering food drive between meals.
Where semaglutide sits in the class
Three compounds dominate the incretin research category. Each one adds receptors:
- Semaglutide. GLP-1 only. Longest published track record. Roughly 15 percent at 68 weeks.
- Tirzepatide. GLP-1 plus GIP. Roughly 21 percent at 72 weeks.
- Retatrutide. GLP-1 plus GIP plus glucagon. Roughly 24 percent at 48 weeks in Phase 2.
Semaglutide remains the first-line research choice for protocols that prioritize the longest published safety and efficacy record over the largest raw signal.
What is the standard Semaglutide research cycle structure?
| Weeks | Weekly dose | Phase |
|---|---|---|
| 1 to 4 | 0.25 mg | Initial titration |
| 5 to 8 | 0.5 mg | First weight signal |
| 9 to 12 | 1.0 mg | Mid-dose maintenance candidate |
| 13 to 16 | 1.7 mg | Step toward top dose |
| 17 onward | 2.4 mg | Top trial dose, maintenance |
Many researchers run 1.0 mg as the long-term maintenance dose for a milder profile, accepting a slower weight curve in exchange for fewer side effects. The 2.4 mg dose is the top of the published trial range and produces the largest signal.
What are the Semaglutide side effects from the literature?
- Nausea, peaks early in each dose step.
- Lower appetite, the mechanism.
- Constipation. More common than diarrhea in the published data.
- Sulfur burps or reflux, occasional.
- Mild fatigue in first 2 weeks of dose step, self-limiting.
- Injection site response, mild redness or tenderness.
How do you reconstitute and store Semaglutide?
Aion ships semaglutide in 5 mg and 10 mg vials. Standard mix for the 5 mg vial: 2 mL of bac water, giving 2.5 mg per mL or 25 mcg per insulin syringe unit. Full walk-through in our reconstitution guide.
- Lyophilized, sealed: refrigerated at 2 to 8 C, stable for months
- Lyophilized, long-term: minus 20 C freezer for multi-year storage
- Reconstituted with bac water: refrigerated, 4 to 6 week use window
What researchers track on a semaglutide cycle
- Bodyweight, weekly morning average
- Waist circumference, monthly
- Resting heart rate, weekly via wearable
- HbA1c, fasting glucose, lipid panel, baseline and at week 12, 24, 40
- Lean body mass (DEXA), baseline and midpoint
- Hunger score (1 to 10), daily
What is the Semaglutide bottom line?
Semaglutide is the slow, steady GLP-1 protocol with the longest research track record. The 40 to 52 week cycle compounds through accumulation, not through any single dramatic month. Stick the titration, log the weekly weight average, let the cycle run its course.
For comparison data, see /research/tirzepatide (21 percent at 72 weeks) and /research/retatrutide (24 percent at 48 weeks in Phase 2). Semaglutide trades the largest signal for the longest published track record.